BiotechTube

Lenvatinib + Nivolumab

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anaplastic Thyroid Cancer

Conditions

Anaplastic Thyroid Cancer

Trial Timeline

Jul 2, 2019 → Dec 1, 2026

NCT ID
NCT05696548

About Lenvatinib + Nivolumab

Lenvatinib + Nivolumab is a phase 2 stage product being developed by Ono Pharmaceutical for Anaplastic Thyroid Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05696548. Target conditions include Anaplastic Thyroid Cancer.

What happened to similar drugs?

0 of 1 similar drugs in Anaplastic Thyroid Cancer were approved

Approved (0) Terminated (0) Active (1)
🔄Alectinib + CrizotinibRochePhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05696548Phase 2Active

Competing Products

20 competing products in Anaplastic Thyroid Cancer

See all competitors
ProductCompanyStageHype Score
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
24
efatutazone + paclitaxelDaiichi SankyoPhase 2
35
Lenvatinib 24 mgEisaiPhase 2
27
durvalumab + tremelimumabAstraZenecaPhase 1
29
PembrolizumabMerckPhase 2
35
LDK378 + AUY922NovartisPhase 1
29
ceritinibNovartisPre-clinical
30
LDK378NovartisPhase 1
29
CeritinibNovartisPhase 2
27
Gemcitabine + ribociclib + sonidegib + trametinib + filgrastimNovartisPhase 1
29
dabrafenib/trametinibNovartisPhase 2
42
Trametinib + PaclitaxelNovartisPhase 1
33
Alectinib + CrizotinibRochePhase 3
44
Sunitinib MalatePfizerPhase 2
35
Crizotinib (PF-02341066)PfizerPhase 2
35
LorlatinibPfizerPhase 2
31
CrizotinibPfizerPhase 1/2
32
Cemiplimab + XL092Regeneron PharmaceuticalsPhase 1
36
Etirinotecan pegolNektar TherapeuticsPhase 2
29
BevacizumabNovocurePhase 2
36